title: Does topoisomerase II-alpha gene amplification provide useful information for treatment selection in patients with breast carcinoma?
authors.forename: Richard
authors.initials: R
authors.lastname: Simon
mesh_terms: D018943:Anthracyclines / Q000008:administration & dosage; D000951:Antigens, Neoplasm / Q000235:genetics*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000235:genetics*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics / Q000401:mortality; D004250:DNA Topoisomerases, Type II / Q000235:genetics*; D004268:DNA-Binding Proteins / Q000235:genetics*; D018572:Disease-Free Survival; D019317:Evidence-Based Medicine; D005260:Female; D005784:Gene Amplification; D006801:Humans; D018579:Patient Selection; D057285:Precision Medicine; D011237:Predictive Value of Tests; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D018943:Anthracyclines; D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; D004268:DNA-Binding Proteins; D004250:DNA Topoisomerases, Type II